COCH

Across TCGA pan-cancer cohorts, COCH mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COCH data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher COCH mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated COCH expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where COCH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.934	0.395	.024	9	view →
CCRCC	OS	Quartile	All	1.000	0.520	.016	4	view →
LSCC	OS	Median	II,III,IV	0.887	0.687	.024	3	view →
LUAD	OS	Median	All	1.000	0.719	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COCH–PDAC (OS)

Open the PDAC breakdown →